For treating advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm and mast cell leukaemia) in adults.

With lenalidomide and dexamethasone is recommended, within its marketing authorisation, as an option for untreated multiple myeloma in adults, when an autologous stem celltransplant is unsuitable.

NICE TA1064: To treat primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults when systemic therapy is suitable.

With etoposide and either carboplatin or cisplatin is recommended as an option for
untreated extensive-stage small-cell lung cancer in adults if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Durvalumab with tremelimumab can be used, within its marketing authorisation, as an option for untreated advanced or unresectable hepatocellular carcinoma (HCC) in adults as per NICE TA1090.

Durvalumab can be used, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults as per NICE TA1099

Enfortumab vedotin with pembrolizumab can be used, within its marketing authorisation, as an option for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable. NICE TA1097

for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (R/R DLBCL), after two or more lines of systemic therapy.

Isatuximab plus bortezomib, lenalidomide and dexamethasone can be used, within its marketing authorisation, as an option for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable. NICE TA1098

For treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments NICE TA947.

For treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on the last treatment.

For newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (AML) in adults, when used:
with standard cytarabine and anthracycline chemotherapy as induction treatment, then
with standard cytarabine chemotherapy as consolidation treatment, then alone as maintenance treatment.